Compare · MDT vs MOVE
MDT vs MOVE
Side-by-side comparison of Medtronic plc. (MDT) and Corvex Inc. (MOVE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and MOVE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.51B, about 308.3x MOVE ($345.4M).
- Over the past year, MDT is down 9.6% and MOVE is up 121.2% - MOVE leads by 130.7 points.
- MOVE has been more active in the news (8 items in the past 4 weeks vs 4 for MDT).
- MDT has more recent analyst coverage (25 ratings vs 0 for MOVE).
- Company
- Medtronic plc.
- Corvex Inc.
- Price
- $83.19+1.43%
- $12.54-3.54%
- Market cap
- $106.51B
- $345.4M
- 1M return
- +3.82%
- -42.75%
- 1Y return
- -9.57%
- +121.16%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
Latest MDT
- A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026
- Medtronic to announce financial results for its first quarter of fiscal year 2027
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
Latest MOVE
- SEC Form EFFECT filed by Corvex Inc.
- SEC Form 424B7 filed by Corvex Inc.
- Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations
- SEC Form S-1 filed by Corvex Inc.
- Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)
- Co-Chief Executive Officer Crystal John Adler Iii converted options into 4,053,677 shares, increasing direct ownership by 109% to 6,414,723 units (SEC Form 4)
- Director Fairbairn Emily converted options into 1,205,282 shares (SEC Form 4)
- Corvex Inc. filed SEC Form 8-K: Other Events, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Fairbairn Emily was granted 135,800 shares, increasing direct ownership by 146% to 228,577 units (SEC Form 4)
- CFO Moreland Christopher was granted 523,211 shares (SEC Form 4)